Loading...
Market
Story
BridgeBio Receives FDA Approval for Heart Disease Drug Attruby™ (acoramidis)
Nov 23, 2024, 12:12 AM
BridgeBio Pharma Inc. (BBIO) has received FDA approval for its drug Attruby™ (acoramidis), a near-complete TTR stabilizer (≥90%), to reduce cardiovascular death and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval will trigger a $500 million payment to BridgeBio under its royalty funding agreement. BridgeBio will provide further details on the Attruby label and access programs in a management call on November 22, 2024, at 8:00 pm ET. The approval is seen as a significant milestone for the company, and the share price is expected to react positively.
View original story
Similar markets
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Acquired by another company • 25%
Forms a major collaboration • 25%
Remains independent • 25%
Other • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%